Need Assistance?
  • US & Canada:
    +
  • UK: +

B2RP-ERa

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

B2RP-ERa is an antimicrobial peptide produced by Hylarana erythraea, Asia. It has antibacterial and antifungal activity.

Category
Functional Peptides
Catalog number
BAT-013058
Molecular Formula
C86H159N23O21S
Molecular Weight
1883.42
Synonyms
brevinin-2-related peptide-ERa (B2RP-ERa); H.erythraea B2RP; Gly-Val-Ile-Lys-Ser-Val-Leu-Lys-Gly-Val-Ala-Lys-Thr-Val-Ala-Leu-Gly-Met-Leu-NH2
Purity
≥96%
Sequence
GVIKSVLKGVAKTVALGML-NH2
Storage
Store at -20°C
1. Efficacy of six frog skin-derived antimicrobial peptides against colistin-resistant strains of the Acinetobacter baumannii group
J Michael Conlon, Agnes Sonnevend, Tibor Pál, Xavier Vila-Farrés Int J Antimicrob Agents. 2012 Apr;39(4):317-20. doi: 10.1016/j.ijantimicag.2011.12.005. Epub 2012 Feb 10.
The emergence of Acinetobacter sp. strains resistant to all antibacterial agents including colistin necessitates the development of new types of antimicrobial agents. Six cationic α-helical frog skin-derived peptides (CPF-AM1, PGLa-AM1, B2RP-ERa, [E4K]alyteserin-1c, [D4K]B2RP and [G4K]XT-7) were selected for this study on the basis of potent growth-inhibitory activity against Gram-negative bacteria and low haemolytic activity against human erythrocytes. All peptides were active against a range of colistin-susceptible [minimum inhibitory concentration (MIC)≤2 μg/mL] and colistin-resistant (MIC≥64 μg/mL) clinical isolates of multidrug-resistant strains of Acinetobacter baumannii and Acinetobacter nosocomialis. The most potent peptides against the colistin-resistant strains were [D4K]B2RP and [E4K]alyteserin-1c (MIC=4-16 μg/mL for both). The MIC values of these peptides against the colistin-susceptible strains were in the same range. The frog peptides show potential for development into drugs to treat infections caused by pandrug-resistant Gram-negative pathogens.
2. Peptides with antimicrobial and anti-inflammatory activities that have therapeutic potential for treatment of acne vulgaris
Suzana Popovic, Edit Urbán, Miodrag Lukic, J Michael Conlon Peptides. 2012 Apr;34(2):275-82. doi: 10.1016/j.peptides.2012.02.010. Epub 2012 Feb 21.
The pathogenesis of acne vulgaris is multifactorial involving infection of the pilosebaceous unit with Propionibacterium acnes and a cytokine-mediated inflammatory response. Five frog skin-derived antimicrobial peptides ([D4k]ascaphin-8, [G4K]XT-7, [T5k]temporin-DRa, brevinin-2GU, and B2RP-ERa), chosen for their low hemolytic activity against human erythrocytes, were assessed for their effects on the growth of clinical isolates of P. acnes and on the release of pro-inflammatory and anti-inflammatory cytokines from peripheral blood mononuclear (PBM) cells. All peptides inhibited the growth of P. acnes with the highest potency exhibited by [D4k]ascaphin-8 (minimum inhibitory concentration, MIC=3-12.5 μM). Release of TNF-α from concanavalin A (ConA)-stimulated PBM cells was significantly reduced by [D4k]ascaphin-8, [G4K]XT-7, brevinin-2GU, and B2RP-ERa (1 and 20 μg/ml) and by [T5k]temporin-DRa (20 μg/ml). Release of IFN-γ from unstimulated PBM cells was significantly reduced by [D4k]ascaphin-8 and brevinin-2GU (1 and 20 μg/ml). No peptide showed significant effects on Il-17 release. Release of the anti-inflammatory cytokines TGF-β, IL-4, and IL-10 from both unstimulated and ConA-treated PBM cells was significantly increased by [T5k]temporin-DRa and B2RP-ERa (1 and 20μg/ml). The potent activities of [D4k]ascaphin-8 and [T5k]temporin-DRa in inhibiting the growth of P. acnes and the release of pro-inflammatory cytokines, and in stimulating the release of anti-inflammatory cytokines suggest a possible therapeutic role in the treatment of acne vulgaris.
Online Inquiry
Verification code
Inquiry Basket